News

BBP-812 and BBP-631 are the lead assets of BridgeBio. An adeno-associated virus (AAV) 9 gene therapy, BBP-812 is intended to treat Canavan disease while BBP-631 is an AAV

With an investment of $38m, the company has doubled the manufacturing capacity of the facility. The expansion included new advanced analytical and chemical development laboratories and construction of

The deal value comprised an upfront cash payment of $1.75bn, apart from further milestone payments in the future. The parties entered an agreement in this regard in June 2023.

An investigational activin signalling inhibitor, sotatercept is intended for usage in adult PAH patients. A regulatory decision on the approval of the therapy is anticipated on 26 March

The designation has been awarded for IDE161 to treat adult patients with advanced or metastatic hormone receptor-positive (HR+), Her2- breast cancer with germline or somatic BRCA 1/2 mutations.

The regulator also approved LIKMEZ as the brand name for ATI-1501. Saptalis is a manufacturing and commercialisation partner of Appili Therapeutics, which has developed ATI-1501 as a liquid

ALTUVIIIO, also known as efanesoctocog alfa, is an antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein used for perioperative management of bleeding, controlling bleeding episodes, and routine prophylaxis. The recommended

This acquisition aligns with Lupin’s strategic goal to strengthen its position in the key therapeutic portfolio in India. The brands agreed to be acquired consists of Piclin (Picosulphate

The company submitted the application in August this year seeking approval for the initiation of Phase I clinical trial of KB408. The regulator, after the 30-day review of